Melanotan I

OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC(C)=O)=O)C(N[C@@H](CO)C(N[C@@H](CCCC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC2=CN=CN2)C(N[C@H](CC3=CC=CC=C3)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(NCC(N[C@@H](CCCCN)C(N4[C@@H](CCC4)C(N[C@H](C(N)=O)C(C)C)=O)=O)=O)=O)CC5=CNC6=CC=CC=C56)=O)=O)=O)=O)=O)=O)=O

[1]Langan EA, et al. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol. 2010 Sep;163 (3) :451-5.|[2]Mahiques-Santos L. Melanotan [Melanotan]. Actas Dermosifiliogr. 2012 May;103 (4) :257-9. Spanish. |[3]Hadley ME, et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006 Apr;27 (4) :921-30.|[4]Hadley ME, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol. 1998;11:575-95.